Patients at the Heart of Research: IMP’s Role in the SIMPATHIC Drug Repurposing Project
Patients at the Heart of Research: IMP’s Role in the SIMPATHIC Drug Repurposing Project The SIMPATHIC project continues to make […]
Latest News
First patient with rare muscle disease treated with own stem cells
First patient with rare muscle disease treated with own stem cells 9 November 2025 Maastricht UMC+ has, for the first
IMP Welcomes FDA Approval of First-Ever Treatment for TK2d
IMP Welcomes FDA Approval of First-Ever Treatment for TK2d International Mito Patient (IMP) is delighted to welcome yesterday’s approval by
Watch our Webinar: The power of nutrition and mitochondrial diseases
Watch our Webinar: The power of nutrition and mitochondrial diseases As part of LHON Awareness Day, we hosted a powerful
From Advocacy to Access: Mito Community Celebrates FDA Milestone
Barth syndrome therapy sets precedent for future treatments targeting mitochondrial dysfunction In a landmark decision, the U.S. Food and Drug
IMP Launches New TK2d Video
IMP Launches New TK2d Video To mark TK2d Awareness Day 2025, we’ve released a new video that amplifyies the voices
IMP Welcomes Three New Members
IMP now has members across three continents We’re delighted to welcome three new members to IMP. With these new members,
Landmark Success for Mitochondrial Donation: A Milestone for Families Worldwide
The birth of eight healthy babies in the UK through mitochondrial donation (also known as Mitochondrial Replacement Therapy) has been
IMP Announces New Board Following Election
IMP is delighted to announce the results of its recent Board elections, confirming a dynamic and diverse leadership team that
Scientists provide first evidence that the drug sildenafil may benefit patients with Leigh syndrome, and particularly those carrying mutations in the mitochondrial gene MT-ATP6.